Privium Fund Management B.V. Dyne Therapeutics, Inc. Transaction History
Privium Fund Management B.V.
- $436 Million
- Q4 2024
A detailed history of Privium Fund Management B.V. transactions in Dyne Therapeutics, Inc. stock. As of the latest transaction made, Privium Fund Management B.V. holds 20,366 shares of DYN stock, worth $245,410. This represents 0.11% of its overall portfolio holdings.
Number of Shares
20,366
Previous 15,016
35.63%
Holding current value
$245,410
Previous $539,000
11.13%
% of portfolio
0.11%
Previous 0.13%
Shares
3 transactions
Others Institutions Holding DYN
# of Institutions
213Shares Held
103MCall Options Held
135KPut Options Held
435K-
Atlas Venture Life Science Advisors, LLC8.02MShares$96.6 Million31.16% of portfolio
-
Black Rock Inc. New York, NY7.39MShares$89 Million0.01% of portfolio
-
Janus Henderson Group PLC London, X07.38MShares$88.9 Million0.09% of portfolio
-
Vanguard Group Inc Valley Forge, PA6.7MShares$80.8 Million0.0% of portfolio
-
Ra Capital Management, L.P. Boston, MA6.38MShares$76.9 Million2.43% of portfolio
About Dyne Therapeutics, Inc.
- Ticker DYN
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 51,765,400
- Market Cap $624M
- Description
- Dyne Therapeutics, Inc., a muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It develops various programs for myotonic dystrophy type 1, duchenne muscular dystrophy, and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and...